Reid Laurence Insider Trading Activity

Average Profitability
41.4%
Insider Buys Quantity
1
Insider Buys Sum
$19,995.00
Insider Sells Quantity
7
Insider Sells Sum
$9.74M

Insider Activity of Reid Laurence

According to the SEC Form 4 filings, Reid Laurence, being in a position of

  1. director at Metagenomi, Inc. Common Stock,
    оver the last 12 months, has bought 20000 shares for $23,401, and sold 0 shares,
    over all time since 2026-09-09, has bought 20000 shares for $23,401, and sold 0 shares.

Biography of Reid Laurence

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $23,4011100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2026-09-09PurchaseMetagenomi, Inc. Common Stock
MGX
director
20,000
0.0541%
$1.17$23,401-11.3%
2014-11-18SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
20,000
0.0271%
$90.67$1.81M+16.54%
2014-08-18SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
27,000
0.0354%
$67.34$1.82M+52.39%
2014-05-19SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
27,000
0.0353%
$57.83$1.56M+57.82%
2014-02-19SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
40,800
0.0609%
$80.06$3.27M-8.2%
2013-11-13SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
27,000
0.0286%
$34.67$936,167+24.52%
2013-05-28SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP and Chief Business Officer
10,000
0.0101%
$18.55$185,500+93.71%
2013-02-08SaleAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
10,000
0.0109%
$16.05$160,500+95.65%
2012-02-21PurchaseAlnylam Pharmaceuticals, Inc.
ALNY
SVP, Chief Business Officer
1,860
0.0036%
$10.75$19,995+41.4%
Total: 9
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.